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INTRODUCTION 
The effects of the opioid crisis in the United States are well-established.  It has reached 
epidemic proportions and causes immense personal, financial, psychological, and medical 
complications to those caught in its addictive clutches.  Many users inject prescription and non-
prescription opiates directly into their veins, allowing for 100% bioavailability and rapid onset of 
the drug’s desired effects.1  While most users are familiar with the very real possibility of death 
from an acute overdose, a lesser known, long-term complication that can result from 
intravenous drug use (IVDU) is a bacterial infection of the valves of the heart called infective 
endocarditis.  The act of sharing or reusing needles, as well as improper cleansing of the skin 
can introduce bacteria directly into the bloodstream, which then seed the valves of the heart, 
resulting in IE.2  This infection has the potential to cause significant chronic medical problems 
that are deleterious to quality of life, requiring multiple hospitalizations, extensive antibiotic 
therapy, and, in some 25-30% of cases, surgical management.3  The mainstay of therapy for IE is 
long-term antibiotics, which is not always feasible or desirable for this patient population for 
several reasons.  Most guidelines recommend four to six weeks of IV antibiotic treatment, 
therefore requiring these antibiotics to be administered via a peripherally inserted central 
catheter (PICC line).4  The presence of a PICC line in a patient known to be an IV drug user 
makes discharge before completion of antibiotic therapy irresponsible due to the very real 
possibility of injecting illicit drugs into the patent venous access site.  Cost is also a significant 
burden, to the patient and facility providing care which will be discussed briefly.  This work will 
serve to analyze the epidemiology, pathophysiology, and treatment options for IV drug use 
associated infective endocarditis with the purpose of answering the question:  In adult 
intravenous drug users with native valve infective endocarditis, are oral antibiotics as effective 
in resolving infection and reducing complications as intravenous antibiotics? A secondary 
objective will include exploration of cost differences. 
BACKGROUND 
Epidemiology 
It is estimated that 21 to 29% of patients with prescription opioids misuse them.5  
Approximately 4 to 6% of these patients will transition to heroin.6  Between 2006 and 2013, 
heroin use in the United States has nearly doubled, and an estimate from the CDC states that 
deaths from heroin overdose nearly quadrupled from 2002 to 2014.7  The population affected 
by infective endocarditis related to IVDU has changed in recent years, with an increasing 
frequency among patients younger than age 34, Caucasians, and females.8  Between 2000 and 
2013, the proportion of patients hospitalized for infective endocarditis whose infections were 
directly related to injection drug use increased from 7% to 12%.  This represents an estimated 
growth from 3,578 cases per year to 8,530 cases per year nationally.8  The CDC has also 
determined that in North Carolina, the incidence of hospitalizations for endocarditis among 
drug-dependent patients has increased twelve-fold since 2010.9  In the general population, IE 
occurs primarily on the left-sided heart structures, more specifically the mitral and aortic 
valves.10  Infective endocarditis involving these valves accounts for approximately 90 to 95% of 
all cases in the United States.10  Interestingly, there is a well-established association of right-
sided endocarditis in IV drug users.  Of all cases of right sided infective endocarditis, is it 
estimated that approximately 76% occurred in IV drug users, and the tricuspid valve is involved 
in 40 to 69% of those cases.11  Not surprisingly, the prevalence of right sided infective 
endocarditis coincides with the population shown to be highest for IV drug use.8 
Pathophysiology 
Infective endocarditis is defined as an infection of the endocardial surface of the heart, 
which may include one or more heart valves, the mural endocardium, or a septal defect.10  Its 
detrimental effects on the heart include severe valvular insufficiency, which may progress to 
congestive heart failure and myocardial abscesses.12  Central to the concept of why infective 
endocarditis is so dangerous to patients is the production of endocardial vegetations.  
Vegetations are comprised of platelets, clotting factors, and inflammatory cells that are 
embedded with high concentrations of bacteria12.  These are diagnosed by echocardiogram 
(Image 1).  These vegetations are able to adhere to damaged endocardial tissues and are 
exceptionally difficult to eradicate, and therefore often require an extended course of antibiotic 
therapy or surgery in order to give the patient the best possible outcome.12   
There are several well-studied mechanisms that help explain how and why IV drug users 
have an increased risk of developing infective endocarditis which we will discuss briefly.  The 
repetitive exposure to particulate matter within solutions of IV drugs can cause damage to the 
valves, particularly the tricuspid valve which acts as a “screen” since it is anatomically the first 
structure exposed to the foreign injected matter.12  Small particles and impurities in the 
injected solution may cross the pulmonary capillaries and abrade the endothelium of the mitral 
and aortic valves as well.12  Direct introduction of bacteria from skin broken by a needle into 
the bloodstream is another origin of infective endocarditis.  The incidence of cutaneous and 
nasal colonization with Staphylococcus aureus has been shown to be higher in IV drug users.  
Staphylococcus aureus also happens to be the most commonly isolated pathogen in cases of 
infective endocarditis associated with IV drug use, although other organisms can be involved as 
well.10  Additionally, there is potential for vasospasm caused by injected impure drugs, 
especially in the case of heroin mixed with vasospastic agents such as cocaine.  This vasospasm 
creates a favorable environment for thrombus formation and bacterial aggregation.12  These 
are the most extensively studied and plausible mechanisms, however further research is always 
warranted to discover more information.   
The clinical presentation of right and left sided infective endocarditis are quite different.  
On physical examination, the majority of patients with right-sided infective endocarditis will 
exhibit a systolic murmur, but they are almost never pathologic13, meaning that the murmur 
itself does not indicate structural heart disease.  Pathologic murmurs are typically associated 
with left-side heart involvement.  The expected characteristics of right-side involvement are 
fever, bacteria in the bloodstream, and as the infection progresses, multiple pulmonary emboli 
as the vegetations break free or cause a vascular insult and produce a clot.13  Therefore, the 
patient may present with chest pain, dyspnea, cough and hemoptysis.  If peripheral embolic 
events or neurological findings are present, it should draw suspicion toward left-sided heart 
involvement.13 
It can be helpful to group complications of right-sided infective endocarditis into cardiac 
or pulmonary.  Multiple sequelae of septic pulmonary emboli include:  pulmonary infarction, 
pulmonary abscess, bilateral pneumothorax, pleural effusion, and empyema.10  Fatal pulmonary 
hemorrhage can occur due to the rupture of aneurysms in the pulmonary arteries.  These 
pulmonary emboli can also result in right ventricular dysfunction to the point of failure and 
worsening tricuspid regurgitation from valvular incompetence.  Tricuspid regurgitation has 
sequelae similar to that of septic pulmonary emboli, including right-sided chamber dilation, 
volume overload, and right ventricular failure.  Other cardiac complications include the 
development of atrial fibrillation or atrial flutter.14 
Current Treatment Guidelines 
According to the 2015 American Heart Association (AHA) Guidelines for Infective 
Endocarditis in Adults, the widely accepted standard of care for IE is 4 to 6 weeks of IV antibiotic 
therapy.  Some less severe Streptococcus infections can be effectively treated with IV 
antibiotics for 2 weeks.15  The choice of antimicrobials will, of course, vary depending on the 
causative microorganism.  Table 1 shows a summary of the various IV antibiotic regimens 
recommended by the AHA for microorganisms causing IE.  Antibiotics such as Penicillin G, 
nafcillin, oxacillin, and vancomycin require central access (as opposed to peripheral or midline 
catheters) if they are to be infused parenterally at standard concentrations for a period of time 
exceeding 2 weeks.16  As Table 1 demonstrates, these IV medications are among the most 
common used to treat IE, especially if the causative microorganism is in the Staphylococcus or 
Streptococcus family. 
 
Table 1:  AHA Recommendations for the Treatment Regimens of Endocarditis 
Microorganism IV Antibiotic Regimen 
Penicillin-susceptible viridans Streptococcus 
or Streptococcus bovis 
Penicillin G or ceftriaxone for 4 weeks 
or 
Penicillin G + gentamicin for 2 weeks 
or 
Ceftriaxone + gentamicin for 2 weeks 
or 
Vancomycin for 4 weeks 
 
Relatively penicillin-resistant viridans 
Streptococcus or S. bovis 
Penicillin G or ceftriaxone for 4 weeks, plus 
gentamicin for 2 weeks 
or 
Vancomycin for 4 weeks 
Penicillin-resistant viridans Streptococcus or 
S. bovis 
Ampicillin + gentamicin for 4 to 6 weeks 
Oxacillin-susceptible staphylococci Nafcillin or oxacillin for 6 weeks, plus 
gentamicin for 3-5 days (optional) 
or 
Cefazolin for 6 weeks, plus gentamicin for 3-5 
days (optional) 
Oxacillin-resistant staphylococcus Vancomycin for 6 weeks 
Enterococcus strains susceptible to penicillin, 
gentamicin, and vancomycin 
Ampicillin + gentamicin for 4-6 weeks 
or 
Penicillin + gentamicin for 4-6 weeks 
or 
Vancomycin and gentamicin for 6 weeks 
Enterococcus strains susceptible to penicillin, 
streptomycin, and vancomycin, and resistant 
to gentamicin 
Vancomycin + streptomycin for 6 weeks 
Enterococcus strains resistant to penicillin, 
but susceptible to aminoglycosides and 
vancomycin 
Ampicillin/sulbactam + gentamicin for 
minimum of 6 weeks 
or 
Vancomycin + gentamicin for 6 weeks 
 
 
METHODS 
In order to address the clinical question at hand, the UNC Health Sciences Library links 
to the PubMed and CINAHL Plus databases were used.  Within the PubMed database, the MeSH 
search builder was utilized and the following terms were added:  “infective endocarditis”, 
“intravenous drug users”, “antibiotics”, “oral antibiotics”, and “intravenous antibiotics”.  In the 
CINAHL Plus database, a search was conducted to include the following terms:  “infective 
endocarditis” AND “intravenous drug use” AND “antibiotics”.  For the latter search term, 
“Include Term in Subject Heading” was specified within the search bar to ensure the focus of 
the resulting articles would be on treatment options and efficacy. 
For the clinical review on this topic, a retrospective cohort study, a systematic review, as 
well as a Cochrane review to compare and contrast have been selected.  Included in the data 
analysis are multiple types of antibiotics, with emphasis placed on the route of administration, 
namely oral and intravenous.  Infections whose etiologies were not related to IV drug use were 
not excluded since the organisms and the disease processes are similar, independent of the 
cause. Risk of bias in the included studies with respect to sequence generation, allocation 
concealment, blinding, incomplete outcome data, and selective reporting was assessed using 
the Cochrane Collaboration’s risk-of-bias assessment tool. 
RESULTS 
Mzabi et al (2016) presented a retrospective cohort study that aimed to determine 
whether a switch from parenteral to oral antibiotics following seven days of treatment with IV 
antibiotics was safe and effective for patients suffering from IE.17  426 cases of confirmed 
infective endocarditis were followed over a total of 13 years (from 2000 to 2013).  The 
infectious agent in 88% of these cases was either Staphylococcus spp. or Streptococcus spp, and 
6% of participants had isolated right-sided IE (although IVDU is not explicitly named as the 
cause).  After an initial phase of IV antibiotic therapy, 214 patients (50%) were switched to an 
oral antibiotic at a median of 21 days after diagnosis of IE.  Patients in the oral antibiotic cohort 
had fewer comorbidities such as heart failure or septic emboli at the start of the study.  Oral 
antibiotics used were amoxicillin alone in 109 cases, or a combination therapy of clindamycin, 
fluoroquinolone, rifampin and/or amoxicillin in 46 cases, according to the susceptibility of the 
microorganisms.  Analysis of these results concludes that a switch to oral antibiotics was not 
associated with an increased risk of mortality.  During follow-up, four reinfections were 
observed in the oral group compared to eight in the IV group.  In this study, switching to oral 
administration was not associated with an increased risk of reinfection and is feasible in less 
severely ill patients.17  
Al-Omari et al (2014) conducted a systematic review of nine observational studies and 
two randomized controlled trials, all of which were determined to be the most applicable after 
applying very discerning exclusion criteria.  The aim of this study was to determine the efficacy 
of oral antibiotic therapy in the treatment of IE, given that the role of oral antibiotic treatment 
for this condition is not well established.  Seven of the observational studies evaluated the use 
of beta-lactams, ciprofloxacin with rifampin, or linezolid as appropriate in sensitivity studies in 
individual cases.  The reported cure rates in these studies were between 77% and 100%, while 
two other observational studies using aureomycin or sulfonamide had failure rates exceeding 
75%.  A clinical trial comparing oral amoxicillin and IV ceftriaxone for IE from Streptococcus spp. 
reported a 100% cure rate, but the reporting had serious methodological limitations. One small 
clinical trial comparing oral ciprofloxacin and rifampin versus conventional intravenous 
antibiotic therapy for uncomplicated right-sided S. aureus IE in intravenous drug users reported 
cure rates of 89% and 90%, respectively.  Drug toxicities were more common in the IV antibiotic 
group (62% versus 3%).  Major limitations of this trial were small sample size, lack of allocation 
concealment, blinding at the delivery of the study drug(s) and assessment of outcomes18.  
Despite these limitations, it can be concluded that an oral regimen of amoxicillin, linezolid, or 
ciprofloxacin with rifampin could be considered when conventional IV antibiotic therapy is not 
possible. 
A.W. Heldman et al (1996) conducted a prospective, randomized, non-blinded trial to 
compare the efficacy and safety of inpatient oral antibiotic treatment versus standard IV 
antibiotic treatment for right-sided staphylococcal endocarditis in IVDUs.  
Oral therapy consisted of ciprofloxacin and rifampin.  IV therapy was oxacillin or vancomycin, 
with gentamicin included for the first 5 days.  Administration of other antibacterial drugs was 
not permitted during the treatment or follow-up periods. Patients with right-sided 
staphylococcal endocarditis participating in the trial received 28 days of inpatient therapy with 
the assigned antibiotics. Test-of-cure blood cultures were obtained during inpatient 
observation 6 and 7 days after the completion of antibiotic therapy, and again at outpatient 
follow-up 1 month later.  Statistical data of the participants in this trial are as follows.  Of 573 
injection drug users who were hospitalized because of a febrile illness, 93 subjects had blood 
cultures positive for Staphylococcus.  Of the 93 subjects with positive blood cultures, 85 fit 
diagnostic criteria for right-sided staphylococcal endocarditis.  44 of these 85 subjects 
completed inpatient treatment and evaluation including test-of-cure blood cultures. Nineteen 
patients received only oral antibiotics as their treatment, and 25 received only IV antibiotics.  
There were four treatment failures, one of them being from the oral antibiotic cohort and three 
from the IV antibiotic cohort.  Drug toxicity was significantly more common in the IV treated 
group (oral, 3%; IV, 62%) consisting largely of oxacillin-associated increases in liver enzymes.19  
Given these results, it can reasonably be concluded that for selected patients with right-sided 
staphylococcal endocarditis, oral ciprofloxacin plus rifampin is effective and is associated with 
less drug toxicity than intravenous therapy.  
 
DISCUSSION 
After reviewing these studies, there are two discrepancies that must be addressed 
regarding the first cited study by Mzabi et al.  This study differed from the other two in that 
there was a prerequisite period of IV antibiotics prior to switching to oral antibiotics, as 
compared to analyzing efficacy of oral antibiotics independently of IV antibiotics.  The decision 
to switch to oral antibiotics was strongly correlated with other prognosis factors such as 
comorbidities and severity criteria. In addition, the timing of the IV to oral switch was highly 
variable from one patient to another.  Furthermore, this study did not specify the etiology of IE 
as being from IV drug use.  Rather, it focused on the infectious agent independent of cause.  It 
must also be noted that while the Al-Omari and Heldman studies did include patients 
specifically noted to have IVDU associated IE, their sample sizes were very small. 
The success of antibiotics in controlling bacterial growth and replication is dependent 
on: a) The susceptibility of the pathogen to the anti-infective that is used; b) The 
pharmacokinetics of this drug (i.e. whether its bioavailability and distribution allow it to reach 
the site of infection in sufficient concentration); and, c) Appropriate duration of therapy.18  
Although the pharmacokinetic profile of oral ampicillin is known to be suboptimal, the studies 
in which this antibiotic was used reported high rates of cure in patients with IE.20  This is likely 
explained by the fact that the organisms causing IE in those series were mainly streptococci and 
staphylococci, and that large doses of oral ampicillin were used.  Oral amoxicillin, on the other 
hand, has excellent bioavailability (>90%) and low binding to serum proteins (17%), which 
maximizes its tissue penetration21, which is needed to effectively sterilize dense vegetations 
found in IE. Typical doses of oral amoxicillin (1 g q8h) produce peak and 6-hour serum 
concentrations of 16ug/ml and 1.1 ug/ml, respectively.22 Further, adding probenecid 1 g to each 
dose of amoxicillin increases its peak and trough serum concentrations by 30% and 4-fold, 
respectively.22  Therefore, while pharmacological considerations make oral amoxicillin a 
plausible alternative for the treatment of IE caused by susceptible bacteria, the clinical evidence 
supporting this approach is still not robust.18  However, because streptococci continue to be a 
leading cause of infective endocarditis (40% - 60% of native valve endocarditis in the 
community setting)14 and oral amoxicillin is inexpensive and widely available, this therapeutic 
approach should be further investigated in adequately designed clinical trials. 
 Staphylococcus aureus is the leading cause of IE among those who acquired the 
infection in healthcare settings and among IV drug users, and the second most prominent cause 
of community acquired IE.23  Ciprofloxacin has bactericidal activity against S. aureus and a 
strong pharmacokinetic profile when given orally (70% bioavailability and serum protein 
binding rate of 30%), but the emergence of resistance during treatment of S. aureus IE is well 
described.24  Similarly, rifampin is bactericidal against S. aureus, has almost complete oral 
bioavailability, and shows little binding to serum proteins; however, it also has a low threshold 
for the development of spontaneous resistance during therapy.25   Newer fluoroquinolones 
such as levofloxacin and moxifloxacin also have a strong pharmacologic profile when given 
orally and are bactericidal against S. aureus, and in contrast to ciprofloxacin, the development 
of in-vivo resistance appears rare.26  Therefore, it would also be reasonable to consider the oral 
administration of these drugs in future studies for the treatment of this infection.  
Oral linezolid has excellent pharmacologic profile (bioavailability >99% and serum 
infections caused by Gram-positive cocci.27  The promising results with the use of oral linezolid 
for the treatment IE reported by Al-Omari et al18 warrant further confirmation in clinical trials.  
The guidelines that have been followed for years have demonstrated a limited role for 
oral antibiotics in the treatment of infective endocarditis.  These opinions, however, were 
largely based on theoretical considerations and anecdotal experience.  The findings of this work 
challenge the guidelines, however there are limitations.  In order for the use of oral antibiotics 
to become a largely accepted practice incorporated into guidelines, higher quality and more 
consistent studies should be performed.  Standard outcome measures and objective measures 
of response to treatment should also be defined and applied in all future studies to ensure 
universally high-quality data collection and analysis.   
Cost is a significant burden to the patient, treatment facility, and the overall medical 
system as a whole.  There is little information available at this time specifically detailing the cost 
in treating IVDUs related IE, however there is one study that provides insight into the financial 
consequences of such an infection.  A 12-month retrospective chart review was conducted at 
Jackson Memorial Hospital in Miami, Florida from 2013 to 2014.  During this period, 423 
patients were admitted for IVDU associated infections.  Only 8% of these patients had private 
insurance.  State-funded Medicaid programs were billed for 41% of patients.  Federally-funded 
Medicare was billed for 15% of patients.  Of the IVDUs in the cohort, 36% were completely 
uninsured. Further financial impact such as lost wages is beyond the scope of this paper.  Care 
for indigent patients at Jackson Memorial Hospital is supported by the taxpayers of Miami-Dade 
County via a 0.5% sales tax levied since 1991 for the Public Health Trust.  During this study, the 
majority of the 423 patients had infections involving skin and soft tissue, with 13% of cases 
being confirmed IE.  The adjusted mean charge for patients without IE was $71,581.  The 
adjusted mean charge for patients with IVDU related IE was significantly higher at $180,31428.  
No data is provided on exact treatment in this study, however it is stated that all IE patients 
received IV antibiotics as part of their therapy. 
Using oral antibiotics as opposed to the well-established IV regimens has significant 
cost-saving potential where appropriate.  For example, referencing the 2015 AHA guidelines 
(see Table 1), it is appropriate to treat IE caused by oxacillin-susceptible S. aureus (OSSA) with a 
6-week course of IV oxacillin.  According to a 2011 study by Weiland et al in which oxacillin was 
used, daily charges for 4g every 6 hours and supplies (not including staff) is $249, with a 6 week 
course totaling $11,329.29  Using the same causative organism, OSSA, in another example, the 
conclusion of Al-Omari et al18 can guide oral treatment.  In this situation, 1g of oral levofloxacin 
daily is an appropriate alternative to IV therapy.  According to the drugs.com price guide 
(November 2018), two 500mg levofloxacin tablets cost $10.1330 which is the daily cost for an 
appropriate dose in a patient with IE.  Therefore, a 6-week course would total $425.46.   
It is also necessary to consider treatment setting in the population of IVDUs. Inpatient 
therapy is an option and may be required depending on severity of illness; however, it is 
inevitably the most expensive, and carries its own set of risks such as hospital acquired 
infections.  Outpatient parenteral therapy (OPAT) is an option for some patients in the general 
population.16  However, a history of illicit injection drug use frequently raises questions about 
the appropriateness of OPAT.  Allowing a patient outside of a supervised facility presents the 
risk of using their PICC line to directly inject other substances.  No clear-cut guidelines exist, and 
the practitioner must weigh the risks and benefits in each case.  Furthermore, the patient must 
be compliant and have the physical ability to complete OPAT. Either the patient, a family 
member, or a designated friend must have the cognitive ability and manual dexterity to infuse 
antibiotics.  The patient's home must have a telephone, running water and, if necessary, a 
refrigerator for medications.16  These added variables associated with OPAT make oral 
antibiotic therapy that much more desirable when possible. 
CONCLUSION 
These studies have demonstrated that oral antibiotics in the treatment of 
uncomplicated infective endocarditis, especially when they are associated with S. aureus and 
Streptococcal spp., are suitable alternatives to the AHA guidelines.  The oral regimens can be 
just as effective, and in some cases, a much better option.  As mentioned previously, the more 
common infectious agents seen in IE from IV drug use are S. aureus and Streptococci.  However, 
it must be restated that the study with the largest sample size cited within this work relied on 
an IV regimen for 3 weeks prior to a switch to oral antibiotics.  Additionally, the participants 
deemed appropriate to receive an oral antibiotic regimen had fewer comorbidities or less 
severe valvular disease than others in the same study.  There are instances in which the options 
of effective intravenous antibiotics are limited, such as in patients with multiple allergies, 
resistant bacteria, or the maintenance of prolonged intravenous access is not desirable.  Oral 
antibiotic regimens can be initiated inpatient, with the potential for quicker discharge and the 
ability to continue treatment from home.  IV antibiotic courses require hospitalization, usually 
for the duration of treatment.   
Remaining at the forefront of all is our obligation as healthcare providers to our 
patients, to educate them on the potential negative outcomes of illicit IV drug use, as well as 
facilitating, to the best of our ability, substance use counseling and rehabilitation. 
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Appendix 
 
Image 1:  Echocardiogram demonstrating a large vegetation in a patient with infective 
endocarditis.  Photo credit:  https://www.rcemlearning.co.uk/references/endocarditis/ 
 
 
 
 
 
 
Cochrane Tool for Risk of Bias: 
 
 
Study 
Random 
Sequence 
Generation 
Allocation 
Concealment 
Blinding of 
Participants 
and 
Personnel 
Blinding of 
Outcome 
Assessment 
Incomplete 
Outcome 
Data 
Selective 
Reporting 
Other 
Bias 
Mzabi 
2016 
High Unclear High Low Low Low Unclear 
Al-Omari 
2014 
High High High High Low High Low 
Heldman 
1996 
Low Low High Low Unclear Low Unclear 
 
 
 
 
Characteristics of Included Studies 
 
Author, year Study Design Sample Size Key Measures Key Findings 
Mzabi, 2016 Retrospective 
Cohort Study 
426 • 214 patients 
(50%) were 
switched to oral 
route at a 
median of 21 
days after 
diagnosis of IE. 
• Oral antibiotics 
were amoxicillin 
alone in 109 
cases or a 
combination 
therapy of 
clindamycin, 
fluoroquinolone, 
rifampicin 
and/or 
amoxicillin in 46 
cases, according 
to the 
susceptibility of 
the 
microorganisms. 
 
 
A switch to oral 
antibiotics 
following a course 
of IV was not 
associated with an 
increased risk of 
mortality or 
reinfection. 
 
Heldman, 1996 Prospective, 
Randomized, Non-
blinded Trial 
93 • Febrile injection 
drug users were 
assigned to 
begin oral or IV 
treatment on 
admission, 
before blood 
culture results 
were available. 
• Oral therapy 
consisted of 
ciprofloxacin 
and rifampin. 
Parenteral 
therapy was 
oxacillin or 
vancomycin, 
plus gentamicin 
for the first 5 
days. 
 
For selected 
patients with right-
sided 
staphylococcal 
endocarditis, oral 
ciprofloxacin plus 
rifampin is 
effective and is 
associated with 
less drug toxicity 
than is intravenous 
therapy. 
 
Al-Omari, 2014 Observational 
Study 
85 • Seven 
observational 
The use of oral 
ciprofloxacin in 
studies 
evaluating the 
use oral beta-
lactams, oral 
ciprofloxacin in 
combination 
with rifampin, 
and linezolid for 
the treatment of 
IE caused by 
susceptible 
bacteria 
reported cure 
rates between 
77% and 100%.  
combination with 
rifampin for 
uncomplicated 
right-sided S. 
aureus IE in IVDUs 
is supported by 
one small clinical 
trial of relatively 
good quality and 
could be 
considered when 
conventional IV 
antibiotic therapy 
is not possible. 
 
Tookes, 2015 Retrospective 
Chart Review 
349 • Discharge 
records/billing 
for all 
emergency 
department 
visits and 
inpatient 
hospitalizations 
were queried 
for drug abuse 
AND infection 
AND 
hospitalization 
between July 1, 
2013 and June 
30, 2014. 
Injection drug use-
related bacterial 
infections 
represent a 
significant 
morbidity for IDUs 
in Miami-Dade 
County and a 
substantial 
financial cost to 
the county 
hospital. 
 
 
 
